Procedural outcomes in patients with dual versus single antiplatelet therapy prior to transcatheter aortic valve replacement

The impact of uninterrupted dual antiplatelet therapy (DAPT) on bleeding events among patients undergoing transcatheter aortic valve replacement (TAVR) has not been well studied. We conducted an analysis of 529 patients who underwent transfemoral TAVR in our centre and were receiving either DAPT or...

Full description

Saved in:
Bibliographic Details
Published in:Scientific reports 2021-07, Vol.11 (1), p.15415-8, Article 15415
Main Authors: Seoudy, Hatim, Thomann, Maren, Frank, Johanne, Lutz, Matthias, Puehler, Thomas, Lutter, Georg, Müller, Oliver J., Frey, Norbert, Saad, Mohammed, Frank, Derk
Format: Article
Language:English
Subjects:
692/4019/2773
692/4019/2776
Aged
Aged, 80 and over
Antiplatelet therapy
Aortic valve
Aortic Valve - surgery
Aortic Valve Stenosis - surgery
Aspirin - adverse effects
Bleeding
Cardiac arrhythmia
Cardiology
Cardiovascular disease
Consortia
Drug Therapy, Combination - methods
Ethics
Female
Follow-Up Studies
Hospitals
Humanities and Social Sciences
Humans
Incidence
Internal medicine
Male
Mortality
multidisciplinary
Patients
Platelet Aggregation Inhibitors - adverse effects
Postoperative Hemorrhage - drug therapy
Postoperative Hemorrhage - etiology
Postoperative Hemorrhage - mortality
Purinergic P2Y Receptor Antagonists - adverse effects
Retrospective Studies
Risk Assessment
Risk Factors
Science
Science (multidisciplinary)
Software
Surgery
Transcatheter Aortic Valve Replacement - adverse effects
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The impact of uninterrupted dual antiplatelet therapy (DAPT) on bleeding events among patients undergoing transcatheter aortic valve replacement (TAVR) has not been well studied. We conducted an analysis of 529 patients who underwent transfemoral TAVR in our centre and were receiving either DAPT or single antiplatelet therapy (SAPT) prior to the procedure. Accordingly, patients were grouped into a DAPT or SAPT group. Following current guidelines, patients in the SAPT group were switched to DAPT for 90 days after the procedure. The primary endpoint of our analysis was the incidence of bleeding events at 30 days according to the VARC-2 classification system. Any VARC-2 bleeding complications were found in 153 patients (28.9%), while major/life-threatening or disabling bleeding events occurred in 60 patients (11.3%). Our study revealed no significant difference between the DAPT vs. SAPT group regarding periprocedural bleeding complications. Based on multivariable analyses, major bleeding (HR 4.59, 95% CI 1.64–12.83, p = 0.004) and life-threatening/disabling bleeding (HR 8.66, 95% CI 3.31–22.65, p 
ISSN:2045-2322
2045-2322
DOI:10.1038/s41598-021-94599-2